Literature DB >> 26606243

Increased Mammalian Target of Rapamycin Signaling Contributes to the Accumulation of Protein Oxidative Damage in a Mouse Model of Down's Syndrome.

Antonella Tramutola1, Chiara Lanzillotta, Andrea Arena, Eugenio Barone, Marzia Perluigi, Fabio Di Domenico.   

Abstract

BACKGROUND: Neurodegenerative diseases are characterized by increased levels of oxidative stress and an altered mammalian target of rapamycin (mTOR)/autophagy axis; however, the mutual relationship between these two events is controversial. Previous studies in Down's syndrome (DS) and Alzheimer's disease (AD) suggested that the accumulation of protein oxidative damage results from the increased free radical production, mainly related to metabolic alterations, mitochondrial degeneration and amyloid-β deposition, and aberrant activity of protein degradative systems.
SUMMARY: This study analyzed mTOR signaling in Ts65Dn mice, a model of DS, at 6 and 12 months of age compared with euploid mice showing the early aberrant hyperphosphorylation of mTOR coupled with the reduction of autophagosome formation. Moreover, the evaluation of protein oxidation shows an increase in protein nitration and protein-bound 4-hydroxynonenal in 12-month-old Ts65Dn mice suggesting the potential involvement of altered autophagy in the buildup of protein oxidative damage. In addition, data obtained on cell culture support the protective role of autophagy in reducing protein oxidation. KEY MESSAGES: Overall, this study provides further evidence for the role of mTOR hyperactivation and reduced autophagy in the accumulation of protein oxidative damage during DS and AD pathologies.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26606243     DOI: 10.1159/000441419

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  18 in total

Review 1.  Exosome release and cargo in Down syndrome.

Authors:  Eric D Hamlett; Angela LaRosa; Elliott J Mufson; Juan Fortea; Aurélie Ledreux; Ann-Charlotte Granholm
Journal:  Dev Neurobiol       Date:  2019-08-06       Impact factor: 3.964

Review 2.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

3.  Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models.

Authors:  Chiara Lanzillotta; Antonella Tramutola; Shelby Meier; Frederick Schmitt; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico; Jose F Abisambra
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  Cystatin C prevents neuronal loss and behavioral deficits via the endosomal pathway in a mouse model of down syndrome.

Authors:  Gurjinder Kaur; Sebastien A Gauthier; Rocio Perez-Gonzalez; Monika Pawlik; Amol Bikram Singh; Benjamin Cosby; Panaiyur S Mohan; John F Smiley; Efrat Levy
Journal:  Neurobiol Dis       Date:  2018-09-01       Impact factor: 5.996

Review 5.  HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.

Authors:  Eugenio Barone; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2016-11-10       Impact factor: 7.376

Review 6.  Exosomal biomarkers in Down syndrome and Alzheimer's disease.

Authors:  Eric D Hamlett; Aurélie Ledreux; Huntington Potter; Heidi J Chial; David Patterson; Joaquin M Espinosa; Brianne M Bettcher; Ann-Charlotte Granholm
Journal:  Free Radic Biol Med       Date:  2017-09-05       Impact factor: 7.376

Review 7.  mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder.

Authors:  M Perluigi; F Di Domenico; E Barone; D A Butterfield
Journal:  Free Radic Biol Med       Date:  2021-04-30       Impact factor: 8.101

8.  Oxidant production and SOD1 protein expression in single skeletal myofibers from Down syndrome mice.

Authors:  Patrick M Cowley; Divya R Nair; Lara R DeRuisseau; Stefan Keslacy; Mustafa Atalay; Keith C DeRuisseau
Journal:  Redox Biol       Date:  2017-07-04       Impact factor: 11.799

Review 9.  mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.

Authors:  David N Franz; Jamie K Capal
Journal:  Orphanet J Rare Dis       Date:  2017-03-14       Impact factor: 4.123

10.  RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome.

Authors:  Eric D Hamlett; Erik Hjorth; Aurélie Ledreux; Anah Gilmore; Marianne Schultzberg; Ann Charlotte Granholm
Journal:  Glia       Date:  2020-01-16       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.